Article Figures & Data
Tables
- Table 1
- Comparison of clinical features between early-onset vs. late-onset MG, all patients.
Variables EOMG (n=71, 72.4%) LOMG (n=27, 27.6%) Total (n=98) P-value n (%) Gender 0.495 Male 29 (29.6) 9 (9.2) 38 (38.8) Female 42 (42.8) 18 (18.4) 60 (61.2) MG classification at onset 0.209 Pure Ocular 39 (39.8) 11 (11.2) 50 (51.0) Generalized 32 (32.7) 16 (16.3) 48 (49.0) Symptoms at onset Ocular 60 (61.2) 25 (25.5) 85 (86.7) 0.292 Fatigability 46 (46.9) 14 (14.3) 60 (61.2) 0.240 Fluctuation 34 (34.7) 10 (10.2) 44 (44.9) 0.335 Bulbar 16 (16.3) 11 (11.2) 27 (27.5) 0.072 Facial weakness 13 (13.3) 6 (6.1) 19 (19.4) 0.662 Respiratory symptoms/failure 6 (6.1) 2 (2.0) 8 (8.1) 0.866 Neck weakness 20 (20.4) 6 (6.1) 26 (25.6) 0.551 Limb weakness 21 (21.4) 8 (8.2) 29 (29.6) 0.996 Antibody status AChR 38 (38.8) 18 (18.4) 56 (57.1) MuSK 2 (2.0) 1 (1.0) 3 (3.1) 0.447 SN 31 (31.6) 8 (8.2) 39 (39.8) NCS (RNS) (n = 66) Positive 34 (51.5) 12 (18.2) 46 (69.7) 0.596 Negative 16 (24.2) 4 (6.1) 20 (30.3) CT scan of the chest (n = 69) Normal 33 (47.8) 12 (17.4) 45 (65.2) 0.592 Abnormal (n=24) 19 (27.5) 5 (7.2) 24 (34.8) Thymic hyperplasia 12 (48.0) 1 (4.0) 13 (54.2) Thymoma 5 (20.0) 3 (12.0) 8 (33.3) Thymic atrophy 2 (8.0) 1 (4.0) 3 (12.5) Thymus pathology (n = 20) Thymic hyperplasia 8 (40.0) 3 (15.0) 11 (55.0) Thymoma 4 (20.0) 2(10.0) 6 (30.0) 0.740 Thymolipoma 2 (10.0) 0 2 (10.0) Normal thymus 1 (5.0) 0 1 (5.0) Treatment outcome(n = 58) Remission 7 (12.1) 0 7 (12.1) Improvement 27 (46.6) 15 (25.9) 42 (72.4) 0.165 Worsening 6 (10.3) 3 (5.2) 9 (15.5) AChR – acetylcholine receptor, CT – computed tomography, EOMG – early onset myasthenia gravis (≤ 49 years), LOMG – late onset myasthenia gravis (> 49 years), MG – myasthenia gravis, MuSK – muscle specific tyrosine kinase, NCS – nerve conduction studies, RNS – repetitive nerve stimulation, SN - seronegative
- Table 2
- Comparison between AChR-positive and double-seronegative MG (excluding MuSK MG patients†).
Variables AChR MG (n =56, 58.9%) SN MG (n =39, 41.1%) Total (n=95) P-value n (%) Gender n (%) Male 23 (24.2) 14 (14.7) 37 (38.9) 0.611 Female 33 (34.7) 25 (26.3) 58 (61.1) Onset EOMG 38 (40.0) 31 (32.6) 69 (72.6) 0.211 LOMG 18 (16.8) 8 (10.5) 26 (27.3) MG types at onset Ocular 25 (26.3) 25 (26.3) 50 (52.6) 0.062 Generalized 31 (32.6) 14 (14.7) 45 (47.4) Symptoms at onset Ocular 49 (51.6) 33 (34.7) 82 (86.3) 0.687 Fatigability 38 (40.0) 20 (21.1) 58 (61.1) 0.103 Fluctuation 26 (27.4) 16 (16.8) 42 (44.2) 0.602 Bulbar 19 (20) 7 (7.4) 26 (27.4) 0.086 Facial weakness 14 (14.7) 4 (4.2) 18 (18.9) 0.071 Respiratory symptoms/failure 6 (6.3) 2 (2.1) 8 (8.4) 0.335 Neck weakness 18 (18.9) 7 (7.4) 25 (26.3) 0.122 Limb weakness 22 (23.1) 5 (5.3) 27 (28.4) 0.005 NCS (RNS) (n = 63) Positive 30 (47.6) 14 (22.2) 44 (68.2) 0.007 Negative 6 (9.5) 13 (20.6) 19 (31.8) Chest CT (n = 67) Normal 26 (47.6) 18 (22.2) 44 (65.7) 0.006 Abnormal 21 (31.3) 02 (3.0) 23 (34.3) Thymic hyperplasia 10 (15.2) 2 (3) 12 (18.2) Thymoma 8 (12.1) 0 8 (12.1) Thymic atrophy 3 (4.5) 0 3 (4.5) Treatment outcome(n = 55) Remission 4 (7.3) 2 (3.6) 6 (10.9) Improvement 28 (50.9) 12 (21.8) 40 (72.7) 0.972 Worsening 6 (10.9) 3 (5.5) 9 (16.4) AChR - acetylcholine receptor, CT - computed tomography, EOMG - early onset myasthenia gravis (≤49 years), LOMG - late onset myasthenia gravis (> 49 years), MG - myasthenia gravis, MuSK - muscle specific tyrosine kinase, NCS - nerve conduction studies, RNS - repetitive nerve stimulation, SN - seronegative, †3 MuSK patients: 2 females and 1 male, 2 with EOMG and 1 LOMG, all generalized disease, 2 with normal CT chest, and 1 with thymic hyperplasia
Treatment Patients, n (%) Pyridostigmine 88 (89.8) Prednisone 63 (64.3) Mycophenolate Mofetil 15 (15.3) Azathioprine 27 (27.6) IVIG 23 (23.5) Rituximab 2(2)
